Brahm Jonathan Yachnin

Brahm Jonathan Yachnin

Auto-generated profile, based on publicly available information

Brahm Jonathan Yachnin

Visterra Inc., Waltham, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Nature
Verified
Journal Article
Open access
PDF file
MPMartin Pacesa
Martin Pacesa
LNLennart Nickel
Lennart Nickel
CSChristian Schellhaas
Christian Schellhaas
JSJoseph Schmidt
Joseph Schmidt
EPEkaterina Pyatova
Ekaterina Pyatova
BCBruno E. Correia
Bruno E. Correia
Protein–protein interactions are at the core of all key biological processes. However, the complexity of the structural features that determine protein–protein interactions makes their design challenging. Here we present BindCraft, an open-source and automated pipeline for de novo protein binder design with experimental success rates of 10–100%. BindCraft leverages the weights of AlphaFold2 (ref. 1) to generate binders with nanomolar affinity without the need for high-throughput screening or experimental optimization, even in the absence of known binding sites. We successfully designed binders against a diverse set of challenging targets, including cell-surface receptors, common allergens, de novo designed proteins and multi-domain nucleases, such as CRISPR–Cas9. We showcase the functional and therapeutic potential of designed binders by reducing IgE binding to birch allergen in patient-derived samples, modulating Cas9 gene editing activity and reducing the cytotoxicity of a foodborne bacterial enterotoxin. Last, we use cell-surface-receptor-specific binders to redirect adeno-associated virus capsids for targeted gene delivery. This work represents a significant advancement towards a ‘one design-one binder’ approach in computational design, with immense potential in therapeutics, diagnostics and biotechnology.

22 April 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
IMI. Ahmad Mirza
I. Ahmad Mirza
BYBrahm J. Yachnin
Brahm J. Yachnin
SWShaozhao Wang
Shaozhao Wang
SGStephan Grosse
Stephan Grosse
HBHélène Bergeron
Hélène Bergeron
ABAlbert M. Berghuis
Albert M. Berghuis

27 April 2012 in Journal of the American Chemical Society
Verified
Journal Article
Open access
BYBrahm J. Yachnin
Brahm J. Yachnin
TSTara Sprules
Tara Sprules
MMMichelle B. McEvoy
Michelle B. McEvoy
PLPeter C. K. Lau
Peter C. K. Lau
ABAlbert M. Berghuis
Albert M. Berghuis
The Baeyer–Villiger monooxygenases (BVMOs) are a family of bacterial flavoproteins that catalyze the synthetically useful Baeyer–Villiger oxidation reaction. This involves the conversion of ketones into esters or cyclic ketones into lactones by introducing an oxygen atom adjacent to the carbonyl group. The BVMOs offer exquisite regio- and enantiospecificity while acting on a wide range of substrates. They use only NADPH and oxygen as cosubstrates, and produce only NADP+ and water as byproducts, making them environmentally attractive for industrial purposes. Here, we report the first crystal structure of a BVMO, cyclohexanone monooxygenase (CHMO) from Rhodococcus sp. HI-31 in complex with its substrate, cyclohexanone, as well as NADP+ and FAD, to 2.4 Å resolution. This structure shows a drastic rotation of the NADP+ cofactor in comparison to previously reported NADP+-bound structures, as the nicotinamide moiety is no longer positioned above the flavin ring. Instead, the substrate, cyclohexanone, is found at this location, in an appropriate position for the formation of the Criegee intermediate. The rotation of NADP+ permits the substrate to gain access to the reactive flavin peroxyanion intermediate while preventing it from diffusing out of the active site. The structure thus reveals the conformation of the enzyme during the key catalytic step. CHMO is proposed to undergo a series of conformational changes to gradually move the substrate from the solvent, via binding in a solvent excluded pocket that dictates the enzyme’s chemospecificity, to a location above the flavin–peroxide adduct where catalysis occurs.

21 October 2014 in ACS Chemical Biology
Verified
Journal Article
Closed access
BYBrahm J. Yachnin
Brahm J. Yachnin
MMMichelle B. McEvoy
Michelle B. McEvoy
RMRoderick J. D. MacCuish
Roderick J. D. MacCuish
KMKrista L. Morley
Krista L. Morley
PLPeter C. K. Lau
Peter C. K. Lau
ABAlbert M. Berghuis
Albert M. Berghuis

1 July 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JVJordan P. Volpato
Jordan P. Volpato
BYBrahm J. Yachnin
Brahm J. Yachnin
JBJonathan Blanchet
Jonathan Blanchet
VGVanessa Guerrero
Vanessa Guerrero
LPLucie Poulin
Lucie Poulin
JPJoelle Pelletier
Joelle Pelletier
Methotrexate is a slow, tight-binding, competitive inhibitor of human dihydrofolate reductase (hDHFR), an enzyme that provides key metabolites for nucleotide biosynthesis. In an effort to better characterize ligand binding in drug resistance, we have previously engineered hDHFR variant F31R/Q35E. This variant displays a >650-fold decrease in methotrexate affinity, while maintaining catalytic activity comparable to the native enzyme. To elucidate the molecular basis of decreased methotrexate affinity in the doubly substituted variant, we determined kinetic and inhibitory parameters for the simple variants F31R and Q35E. This demonstrated that the important decrease of methotrexate affinity in variant F31R/Q35E is a result of synergistic effects of the combined substitutions. To better understand the structural cause of this synergy, we obtained the crystal structure of hDHFR variant F31R/Q35E complexed with methotrexate at 1.7-A resolution. The mutated residue Arg-31 was observed in multiple conformers. In addition, seven native active-site residues were observed in more than one conformation, which is not characteristic of the wild-type enzyme. This suggests that increased residue disorder underlies the observed methotrexate resistance. We observe a considerable loss of van der Waals and polar contacts with the p-aminobenzoic acid and glutamate moieties. The multiple conformers of Arg-31 further suggest that the amino acid substitutions may decrease the isomerization step required for tight binding of methotrexate. Molecular docking with folate corroborates this hypothesis.

28 December 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
KBKristin M. Blacklock
Kristin M. Blacklock
BYBrahm Jonathan Yachnin
Brahm Jonathan Yachnin
GWG. Andrew Woolley
G. Andrew Woolley
SKSagar D. Khare
Sagar D. Khare